Healthcare stocks were flat to lower premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down a slight 0.2%.
Kodiak Sciences (KOD) stock was up more than 99% after the company said its two experimental eye drugs, Zenkuda and tabirafusp-ted, met primary endpoints in a Phase 3 study in patients with wet age-related macular degeneration.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.